Melkart

Vildagliptin, the active ingredient in Melkart, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control through enhanced insulin secretion and reduced glucagon release.

GNH USA supplies Melkart as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets and adhering to stringent quality standards with comprehensive logistics support.

Melkart (vildagliptin) is used in the management of type 2 diabetes, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. - Combination therapy with metformin: enhances overall glucose reduction when used together. - Adjunct to diet and exercise: supports blood sugar management in patients who have not achieved targets with lifestyle measures alone.

Vildagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms such as cough or sore throat. - Dizziness: occasional light‑headed feeling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: rare skin blistering disorder.

When prescribing vildagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose or avoid use in severe impairment. - Hepatic impairment: monitor liver enzymes and use with caution in moderate liver disease. - Elderly patients: start at the lowest effective dose and monitor for hypoglycemia. - Concomitant sulfonylureas or insulin: increased risk of hypoglycemia; adjust co‑medication as needed. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Vildagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycemia when combined. - Drugs that cause pancreatitis (e.g., azathioprine, didanosine): increase risk of pancreatic inflammation.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce vildagliptin plasma concentrations, decreasing effectiveness. - Diuretics (thiazides): can affect glucose homeostasis, requiring closer glycemic monitoring. - ACE inhibitors or ARBs: monitor renal function and electrolytes when used together.